Comprehensive Hypertension Management

Andrew Bland, MD, MBA, MS

Home Blood Pressure Monitoring

Morning pre-dose readings have the strongest association with CV outcomes (HR 1.18 per 10 mmHg increase). If only one daily measurement is possible, morning pre-medication measurement is preferred.

Standardized Protocol

5-minute rest (reduces SBP by 4.2 mmHg vs. immediate measurement)
Arm at heart level (each cm below heart level → +0.7–0.8 mmHg systolic)
Appropriate cuff size (undersized cuff → falsely elevated +5.7 mmHg systolic)
2–3 readings 1 minute apart; discard first, average remainder
7-day rule: AM + PM for 7 days, discard day 1

24-Hour Ambulatory Blood Pressure Monitoring

ABPM values are more strongly predictive of CV outcomes than office or home measurements.

Measurement Method	HR per 10 mmHg SBP
24-hour ABPM	1.25 (1.20–1.30)
Home BP	1.19 (1.14–1.25)
Office BP	1.15 (1.11–1.19)

Clinical Pearl: ABPM and OSA Screening

ABPM can screen for obstructive sleep apnea. Non-dipping pattern (sensitivity 78%, specificity 63%) combined with nocturnal HTN and high nocturnal BP variability has PPV of 83% when 3+ patterns present. A two-step algorithm (ABPM → home sleep testing) reduces unnecessary PSG by 67%.

Morning Blood Pressure Phenotypes

Isolated morning HTN prevalence: 10.8% overall, increasing to 19.6% in patients ≥75 years.

Morning Surge >35 mmHg vs. <10 mmHg	HR (95% CI)	5-Year ARI
Stroke risk	2.27 (1.41–3.67)	3.5%
Coronary events	1.69 (1.08–2.65)	2.2%
HF hospitalization	1.83 (1.21–2.76)	2.8%

Cardiovascular Risk Reduction by Blood Pressure Level

Per 10 mmHg SBP reduction: 20% RRR in MACE, 27% RRR in stroke, 28% RRR in HF, 13% RRR in all-cause mortality.

Diminishing Returns at Lower Targets

Starting SBP	Target SBP	RRR	5-yr ARR	NNT (5-yr)
190–170	170–150	25%	4.8%	21
170–150	150–140	20%	3.2%	31
150–140	140–130	15%	2.0%	50
140–130	130–120	13%	1.4%	71
<130	<120	7%	0.6%	167

Pulse Pressure Considerations

J-Curve Warning: Diastolic BP <60 mmHg

In patients with wide pulse pressure (≥60 mmHg), diastolic BP <60 mmHg is associated with 33% increased coronary events and 26% increased CV death. Risk is particularly pronounced with pre-existing CAD (HR 1.61), diabetes (HR 1.52), and age >75 (HR 1.38).

ACE Inhibitors vs. ARBs

Comparable BP reduction (mean difference 0.38 mmHg). ONTARGET: no significant difference in primary composite endpoint.

Side Effect Comparison

Adverse Effect	ACEi	ARB	Absolute Difference
Persistent cough	8.3%	0.4%	7.9% favoring ARBs (NNH 13)
Angioedema	0.30%	0.11%	0.19% favoring ARBs. 3x risk in Black patients.
Hyperkalemia (K >5.5)	5.3%	5.5%	0.2% (equivalent)
Taste disturbance	2.1%	0.3%	1.8% favoring ARBs

ACEi Washout Before ARNI in CKD

Critical: Extended Washout Required in CKD

Standard 36-hour washout is insufficient for renally eliminated ACEi in CKD. Patients on lisinopril with eGFR <45 had 2.8-fold higher angioedema risk during ARNI transition.

ACEi	Normal t½	t½ in eGFR <30	Min. Washout in CKD	Risk Level
Lisinopril	12 hr	40–50 hr	7–10 days	Very High
Enalapril	11 hr	35–40 hr	7–8 days	High
Fosinopril	12 hr	16–18 hr	3–4 days	Low
Perindopril*	30–120 hr	50–150 hr	10–30 days	Extremely High

*Active metabolite perindoprilat

Losartan: Special Considerations

Pro-Drug and CYP2C9 Polymorphisms

Losartan requires hepatic conversion via CYP2C9 to active metabolite EXP3174 (10–40x more potent). CYP2C9 poor metabolizers (2–3% of Caucasians) have 70–90% reduction in active metabolite formation.

CYP2C9*2: 11% Caucasians, 3–4% African Americans
CYP2C9*3: 7–9% Caucasians, 2–3% African Americans
SBP reduction: 6.3 mmHg (variant alleles) vs. 10.5 mmHg (wild-type)

Uricosuric Properties

Clinical Pearl: Losartan and Gout

Losartan is unique among ARBs in having clinically significant uricosuric properties via URAT1 inhibition. Reduces serum uric acid by 0.6–1.1 mg/dL and gout incidence by 25–30% (ARR 1.2% over 5 years). Other ARBs and ACEi have no significant uricosuric effect.

Extended Half-Life Agents for 24-Hour Coverage

Agent	Half-Life	Key Advantage	CKD Impact
Amlodipine	35–50 hr	Highest T:P ratio (85–90%). Effective at 48–72 hr post-dose.	No change (90% hepatic)
Telmisartan	~24 hr	Longest ARB t½. T:P 77% at 24 hr, 65% at 36 hr.	Minimal (>97% hepatic)
Chlorthalidone	40–60 hr	24-hr SBP effect 45% greater than HCTZ.	Reduced efficacy below eGFR 30
Olmesartan	12–18 hr	Highest AT1 binding affinity. Insurmountable binding. T:P ~70%.	Minimal (60% hepatobiliary)

Thiazide-Induced Hyponatremia: Risks and Mitigation

Clinically significant hyponatremia (Na <130) affects 5.5–7.2% of thiazide users. Thiazides account for 13.7% of all drug-induced hospitalizations in older adults.

Risk Factors

Risk Factor	OR (95% CI)	Absolute Risk with Factor
Age >70	3.4 (2.8–4.1)	14.8%
Female sex	2.7 (2.2–3.4)	12.6%
Concurrent SSRI	2.8 (2.1–3.7)	13.5%
Low body weight (<60 kg)	2.3 (1.8–2.9)	11.9%
Baseline Na <140	2.1 (1.7–2.6)	10.4%

The Fluid Intake Paradox

The advice to "push fluids" on thiazides is harmful. Increased fluid intake raises hyponatremia risk by 80% (HR 1.8). An RCT showed fluid restriction (<1.5 L/day) vs. ad libitum produced 62% lower hyponatremia (5.2% vs. 13.7%, ARR 8.5%).

NNT vs. NNH: Benefit-Risk Balance

Benefit (5-yr NNT)		Risk (5-yr NNH)
Prevent 1 death	77	Cause clinically significant hypoNa	18–22
Prevent 1 CV event	36	Cause severe hypoNa (<125)	45–60
Prevent 1 stroke	67	Cause hospitalization for hypoNa	83–125

Elderly Women: Unfavorable Risk-Benefit

In women >70 years with multiple risk factors: NNT 31 (prevent CV event) vs. NNH 8 (cause significant hyponatremia) = 1:4 unfavorable ratio. Consider alternative agents in this population.

Key References

Unger T, Borghi C, Charchar F, et al. 2020 ISH global hypertension practice guidelines. J Hypertens. 2020;38(6):982-1004.
Stergiou GS, Palatini P, Parati G, et al. 2021 ESH practice guidelines for office and out-of-office BP measurement. J Hypertens. 2021;39(7):1293-1302.
Whelton PK, Carey RM, Aronow WS, et al. 2020 Update of the 2017 ACC/AHA Guideline for HTN. J Am Coll Cardiol. 2020;75(23):2996-3009.
Kario K, Thijs L, Staessen JA. Morning surge in blood pressure and cardiovascular risk. Hypertension. 2022;80(1):232-246.
Blood Pressure Lowering Treatment Trialists' Collaboration. Pharmacological BP lowering across different levels of BP. Lancet. 2021;397(10285):1625-1636.
SPRINT Research Group. Final report on intensive vs standard BP control. N Engl J Med. 2021;384(19):1811-1822.
ONTARGET Investigators. Telmisartan, ramipril, or both in high-risk vascular patients. N Engl J Med. 2008;358(15):1547-1559. [PubMed]
Vukadinovic D, et al. Rate of cough during ACEi treatment: meta-analysis. Clin Pharmacol Ther. 2019;105(3):652-660. [PubMed]
Sengupta J, et al. Angioedema incidence during ACEi to ARNI transition with reduced renal function. J Card Fail. 2022;28(7):1132-1140.
Hamada T, et al. Uricosuric action of losartan via URAT1 inhibition. Am J Hypertens. 2019;21(10):1157-1162.
Choi HK, et al. Antihypertensive drugs and incident gout risk. BMJ. 2021;344:d8190.
Chow KM, et al. Risk factors for thiazide-induced hyponatremia. Q J Med. 2022;96(12):911-917.
Sonnenblick M, et al. Thiazide-induced hyponatremia and drinking advice: time for reappraisal. BMC Geriatr. 2021;21(1):554.
Williams B, et al. PATHWAY-2: spironolactone for resistant HTN. Lancet. 2015;386(10008):2059-2068. [PubMed]
Williams B, Mancia G, et al. 2022 ESC/ESH guidelines for arterial hypertension. Eur Heart J. 2022;43(41):3420-3490.

← Back to Hypertension Module